Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.
Cross-talk between tumour and stromal cells can profoundly influence cancer cell invasion by increasing the availability of mitogenic peptides such as endothelin-1 (ET-1). Endothelin-1 is elevated in men with metastatic prostate cancer (PC), and can exert both an autocrine (epithelial) and a paracrine (stromal) influence on growth. Endothelin-1 is generated from its inactive precursor big-ET-1 by endothelin-converting enzyme 1 (ECE-1). We and others have demonstrated that ECE-1 expression is significantly elevated in tumours and surrounding stromal tissue. Our current data show siRNA-mediated knockdown of stromal ECE-1 reduces epithelial (PC-3) cell invasion in coculture. Interestingly, readdition of ET-1 only partially recovers this effect suggesting a novel role for ECE-1 independent of ET-1 activation. Parallel knockdown of ECE-1 in both stromal and epithelial compartments results in an additive decrease in cell invasion. We extrapolated this observation to the four recognised isoforms ECE-1a, ECE-1b, ECE-1c and ECE-1d. Only ECE-1a and ECE-1c were significant but with reciprocal effects on cell invasion. Transient ECE-1c overexpression increased PC-3 invasiveness through matrigel, whereas transient ECE-1a expression suppressed invasion. Furthermore, transient ECE-1a expression in stromal cells strongly counteracts the effect of transient ECE-1c expression in PC-3 cells. The ECE-1 isoforms may, therefore, be relevant targets for antiinvasive therapy in prostate and other cancers.
Lambert
L A
LA
Proteolysis Research Group, Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK. bmblad@bmb.leeds.ac.uk
Whyteside
A R
AR
Turner
A J
AJ
Usmani
B A
BA
D016282:Aspartic Acid Endopeptidases / Q000378:metabolism*; D001483:Base Sequence; D045744:Cell Line, Tumor; D017077:Culture Media, Conditioned; D000072396:Endothelin-Converting Enzymes; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D008297:Male; D008666:Metalloendopeptidases / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D034741:RNA, Small Interfering
D017077:Culture Media, Conditioned; D007527:Isoenzymes; D034741:RNA, Small Interfering; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; D000072396:Endothelin-Converting Enzymes
FEBS Lett. 1995 Sep 4;371(2):140-4
7672114
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S354-6
11078419
Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11838-43
17592116
Eur J Biochem. 1999 Sep;264(2):341-9
10491078
Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31
10745023
Biochem J. 1997 Dec 15;328 ( Pt 3):871-7
9396733
Clin Sci (Lond). 2002 Aug;103 Suppl 48:314S-317S
12193112
FEBS Lett. 2007 Sep 18;581(23):4501-6
17761169
FEBS Lett. 1998 Mar 13;424(3):183-7
9539147
J Med Chem. 2005 Jan 27;48(2):483-98
15658862
Nat Med. 1995 Sep;1(9):944-9
7585222
Br J Cancer. 2004 Apr 19;90(8):1577-82
15083188
Nat Med. 1998 Jan;4(1):50-7
9427606
Cancer Cell. 2004 Jan;5(1):67-78
14749127
Science. 1997 Mar 28;275(5308):1943-7
9072974
Clin Cancer Res. 2001 May;7(5):1370-7
11350908
Lab Invest. 2000 Nov;80(11):1681-9
11092528
Breast Cancer Res Treat. 2007 Dec;106(3):361-9
17295044
J Mol Med (Berl). 1997 Jul;75(7):512-21
9253714
Cancer Res. 2005 Oct 1;65(19):8887-95
16204060
J Biol Chem. 1994 Jul 15;269(28):18275-8
8034569
Br J Cancer. 2000 Feb;82(4):990-7
10732776
J Biol Chem. 2003 Jan 3;278(1):545-55
12393864
Int J Cancer. 2006 Apr 1;118(7):1645-52
16217751
Nat Rev Cancer. 2007 Feb;7(2):139-47
17218951
Am J Pathol. 2000 Dec;157(6):1863-74
11106559
Exp Biol Med (Maywood). 2006 Jun;231(6):1106-10
16741058
Mol Pharmacol. 2001 Dec;60(6):1332-42
11723240
Urology. 2007 Jul;70(1):209-15
17656249
Cancer Invest. 2001;19(8):779-82
11768030
Cancer Res. 2006 May 15;66(10):5201-8
16707444